SEARCH

SEARCH BY CITATION

References

  • 1
    Allgayer H. Sulfasalzine and 5-ASA compounds. Gastroenterol Clin North Am 1992; 21: 643 58.
  • 2
    Meyers B, Evans DNW, Rhodes J, et al. Metabolism and urinary excretion of 5-aminosalicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. Gut 1987; 28: 196 200.
  • 3
    Willoughby CP, Cowan RE, Gould SR, Machell RJ, Stewart JB. Double-blind comparison of Olsalazine and Sulfasalazine in active ulcerative colitis. Scand J Gastroenterol 1988; 23(Suppl 148): 40.
  • 4
    Rao SSC, Dundas SAC, Holdsworth CD, Cann PA, Palmer KR, Corbett CL. Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double-blind study. Gut 1989; 30: 675 9.
  • 5
    Feurle GE, Theuer D, Velasco S, et al. Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomised double blind trial. Gut 1989; 30: 1354 61.
  • 6
    Ewe K, Eckardt V, Kanzler G. Treatment of ulcerative colitis with olsalazine and sulphasalazine: efficacy and side-effects. Scand J Gastroenterol 1988; 23(Suppl. 148): 70 5.
  • 7
    Hetzel DJ, Shearman DJC, Bochner F, et al. Azodisalicylat (olsalazine) in the treatment of active ulcerative colitis. A placebo controlled trial and assessment of drug disposition. J Gastroenterol Hepatol 1986; 1: 257 66.
  • 8
    Meyers S, Sachar DB, Present DH, Janowitz HD. Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant to sulfasalazine. Gastroenterology 1987; 93: 1255 62.
  • 9
    Selby WS, Barr GD, Ireland A, Mason CH, Jewell DP. Olsalazine in active ulcerative colitis. Br Med J 1985; 291: 1373 5.
  • 10
    Hardy JG, Healy JNC, Reynolds JR. Evaluation of an enteric-coated delayed-release 5-aminosalicylic acid tablet in patients with inflammatory bowel disease. Aliment Pharmacol Ther 1987; 1: 273 80.
  • 11
    Rachmilewitz D on behalf of an international study group. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomized trial. Br Med J 1989; 298: 82 6.
  • 12
    Blackwelder WC. ‘Proving the Null Hypothesis’ in Clinical Trials. Control Clin Trials 1982; 3: 345 53.
  • 13
    ICH Topic E9. Statistical principles for clinical trials, step 3, draft. 17 January 1997.
  • 14
    Courtney MG, Numnes DP, Bergin CF , et al. Randomized comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis. Lancet 1992; 339: 1279 81.
  • 15
    Staerk Laursen L, Stokholm M, Bukhave K, Rask-Madsen J, Lauritsen K. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion. Gut 1990; 31: 1271 6.
  • 16
    Hanauer S, Schwartz J, Robinson M , et al. and the Pentasa® Study group. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Am J Gastroenterol 1993; 88: 1188 97.
  • 17
    Schröder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. N Engl J Med 1987; 317: 1625 9.
  • 18
    De Dombal FT, Dew MJ, Hanauer SB, et al. Towards an optimal dosage of oral 5-ASA in ulcerative colitis. Gastroenterol Int 1992; 5 (3): 155 61.
  • 19
    Sandberg-Gertzén H, Järnerot G, Kraaz W. Azodisal sodium in the treatment of ulcerative colitis. A study of tolerance and relapse-prevention properties. Gastroenterology 1986; 90: 1024 30.
  • 20
    Ireland A, Mason Ch, Jewell DP. Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis. Gut 1988; 29: 835 7.